BiotechTube
invIOs

invIOs

Vienna, Austria· Est.
invios.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $27.5M

Overview

invIOs is a Vienna-based biotech developing novel immuno-oncology therapies, with a pipeline featuring both an autologous cell therapy platform (EPiC) and a small molecule program. Its lead asset, APN401, is in Phase 1 trials for solid tumors, while other programs target glioblastoma, AML, and enhanced CAR therapies. The company is privately held, raised a €8.2M Series A, and is led by a team with deep expertise in oncology drug development and Austrian biotech.

Oncology

Technology Platform

EPiC cell therapy platform for modifying autologous immune cells (PBMCs/TILs) and a small molecule discovery program for oral immune activators.

Funding History

2
Total raised:$27.5M
Series A$25M
Seed$2.5M

Opportunities

The significant unmet need in solid tumor immunotherapy presents a large addressable market.
Success with its oral small molecule (INV501) could offer a more scalable and convenient treatment modality.
Positive Phase 1b data for APN401 could attract partnership deals and further investment.

Risk Factors

High clinical risk associated with novel immuno-oncology mechanisms in challenging solid tumors.
Dependence on raising additional capital to advance its pipeline beyond the current Series A funding.
Intense competition in the CAR-T and immune activator space from larger, better-funded entities.

Competitive Landscape

invIOs operates in the highly competitive immuno-oncology field, competing with large pharma and biotech companies developing cell therapies (CAR-T, TILs) and small molecule immune modulators. Its differentiation lies in its specific platform approaches, like Cbl-b silencing and multi-antigen targeting, aimed at overcoming common resistance mechanisms in the tumor microenvironment.

More companies in Immunotherapy / Immuno-Oncology →More companies in Austria →